AbbVie said net earnings for the three months ended in September were $2.31 billion, or $1.29 a share, vs. $1.88 billion, or $1.26 a share, in the comparable year-earlier quarter.
On an adjusted basis, AbbVie earned $2.83 a share, above the $2.76 a share expected by analysts polled by FactSet.
Global sales jumped 52% to $12.9 billion vs. $8.4 billion a year ago, also ahead of analysts' forecasts of sales of $12.7 billion.
U.S. sales of the company's blockbuster arthritis treatment Humira rose 4.1% to $5.14 billion as U.S. gains offset international declines.
Net revenue from its hematologic oncology portfolio, meanwhile, came in at $1.72 billion, an increase of more than 16%, thanks to strong global sales of its Imbruvica and Venclexta cancer-fighting treatments.
Revenue from Botox used in cosmetic treatments came in at $393 million; revenue from AbbVie's "aesthetics" portfolio totaled $967 million, AbbVie said.
Latest Videos From TheStreet and Jim Cramer:
- Unmasking Winners in PPE Market
- Is PPE an Investing Opportunity Amid Vaccine Race?
- Kind Launches New Energy Bar: The Story Behind It
- PPE and the Supply Chain: How O2 Industries Adapted During Pandemic
- Nightmare on Wall Street: Spooky Terms Explained
- PPE and Your Portfolio: Inside a Disruptive Industry